Acute coronary syndrome - The present and future role of biomarkers1)

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 9, 2013, Pages 1699-1706

  Lindahl, Bertil ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute coronary syndromes; Biomarkers; Diagnosis; Prognosis

Indexed keywords

ADRENOMEDULLIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; COPEPTIN; CYSTATIN C; GELATINASE B; GROWTH DIFFERENTIATION FACTOR 15; HORMONE PRECURSOR; ISCHEMIA MODIFIED ALBUMIN; MICRORNA; MYELOPEROXIDASE; PREGNANCY ASSOCIATED PLASMA PROTEIN A; TROPONIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DISEASE COURSE; DOSE RESPONSE; EARLY DIAGNOSIS; ELECTROCARDIOGRAM; GENE EXPRESSION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATORY DISEASE; INVASIVE PROCEDURE; KIDNEY FUNCTION; META ANALYSIS (TOPIC); NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMATIC REVIEW (TOPIC);

ACUTE CORONARY SYNDROME; BIOLOGICAL MARKERS; CLINICAL LABORATORY TECHNIQUES; HUMANS; PROGNOSIS; RISK ASSESSMENT;

EID: 84888096011     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0074     Document Type: Review

References (59)

1. Fuster V, Badimon L, Badimon J, Chesebro J. The pathogenesis of coronary artery disease and the acute coronary syndromes (second of two parts). N Engl J Med 1992;326: 310-8.
2. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Eur Heart J 2012;33: 2551-67.
3. Schmidt M, Jacobsen J, Lash T, Bøtker H, Sørensen H. 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study. Br Med J 2012;344:e356.
4. Vamos EP, Millett C, Parsons C, Aylin P, Majeed A, Bottle A. Nationwide study on trends in hospital admissions for major cardiovascular events and procedures among people with and without diabetes in England, 2004-2009. Diabetes Care 2012;35: 265-72.
5. Wilhelmsen L, Welin L, Svärdsudd K, Wedel H, Eriksson H, Hansson PO, et al. Secular changes in cardiovascular risk factors and attack rate of myocardial infarction among men aged 50 in Gothenburg, Sweden. Accurate prediction using risk models. J Intern Med 2008;263: 636-43. (Pubitemid 351678585)
6. Rogers WJ, Frederick PD, Stoehr E, Canto JG, Ornato JP, Gibson CM, et al. Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J 2008;156: 1026-34.
7. Jernberg T, Johanson P, Held C, Svennblad B, Lindbäck J, Wallentin L. Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. J Am Med Assoc 2011;305: 1677-84.
8. Chan D, Ng L. Biomarkers in acute myocardial infarction. BMC Med 2010;8:34.
9. Scirica B. Acute coronary syndrome: emerging tools for diagnosis and risk assessment. J Am Coll Cardiol 2010;55: 1403-15.
10. Karmen A, Wroblewski F, LaDue JS. Transaminase activity in human blood. J Clin Invest 1954;34: 126-33.
11. Adams J, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990s? Circulation 1993;88: 750-63. (Pubitemid 23228075)
12. Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012; 58: 54-61.
13. Mousavi N, Czarnecki A, Kumar K, Fallah-Rad N, Lytwyn M, Han S-Y, et al. Relation of biomarkers and cardiac magnetic resonance imaging after marathon running. Am J Cardiol 2009;103: 1467-72.
14. Wilson SR, Sabatine MS, Braunwald E, Sloan S, Murphy SA, Morrow DA. Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: observations from the PROTECT-TIMI 30 Trial. Am Heart J 2009;158: 386-91.
15. Venge P, Johnston N, Lindahl B, James S. Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocardial ischemia. J Am Coll Cardiol 2009;54: 1165-72.
16. Eggers KM, Oldgren J, Nordenskjöld A, Lindahl B. Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. Am Heart J 2004;148: 574-81. (Pubitemid 39349374)
17. Eggers KM, Venge P, Lindahl B. High-sensitive cardiac troponin T outperforms novel diagnostic biomarkers in patients with acute chest pain. Clin Chim Acta 2012;413: 1135-40.
18. Lin S, Yokoyama H, Rac VE, Brooks SC. Novel biomarkers in diagnosing cardiac ischemia in the emergency department: a systematic review. Resuscitation 2012;83: 684-91.
19. McCann CJ, Glover BM, Menown IB, Moore MJ, McEneny J, Owens CG, et al. Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T. Eur Heart J 2008;29: 2843-50.
20. Apple FS, Smith SW, Pearce LA, Murakami MM. Assessment of the multiple-biomarker approach for diagnosis of myocardial infarction in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem 2009; 55: 93-100.
21. Heidenreich PA, Alloggiamento T, Melsop K, McDonald KM, Go AS, Hlatky MA. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol 2001;38: 478-85. (Pubitemid 32721777)
22. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000;343: 1139-47.
23. Lindahl B, Diderholm E, Lagerqvist B, Venge P, Wallentin L. Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol 2001;38: 979-86. (Pubitemid 32912698)
24. James SK, Oldgren J, Lindbäck J, Johnston N, Siegbahn A, Wallentin L. An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease. Am Heart J 2005;149: 619-26.
25. Correia L, Esteves J. C-reactive protein and outcomes in acute coronary syndromes: a systematic review and meta-analysis. Arq Bras Cardiol 2011;97: 76-85.
26. He L-P, Tang X-Y, Ling W-H, Chen W-Q, Chen Y-M. Early C-reactive protein in the prediction of long-term outcomes after acute coronary syndromes: a meta-analysis of longitudinal studies. Heart 2010;96: 339-46.
27. James SK, Armstrong P, Barnathan E, Califf R, Lindahl B, Siegbahn A, et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol 2003;41: 916-24. (Pubitemid 36315530)
28. Christenson RH. Preamble: National Academy of clinical biochemistry laboratory medicine practice guidelines for utilization of biomarkers in acute coronary syndromes and heart failure. Clin Biochem 2008;41: 208-9. (Pubitemid 351240896)
29. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 2004;6: 257-60. (Pubitemid 38253043)
30. Baxter GF. Natriuretic peptides and myocardial ischaemia. Basic Res Cardiol 2004;99: 90-3. (Pubitemid 38325022)
31. Lindahl B, Lindbäck J, Jernberg T, Johnston N, Stridsberg M, Venge P, et al. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during InStability in coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol 2005;45: 533-41. (Pubitemid 40222247)
32. Wiviott SD, de Lemos JA, Morrow DA. Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes. Clin Chim Acta 2004;346: 119-28. (Pubitemid 38901042)
33. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003;108: 275-81. (Pubitemid 36899016)
34. Santopinto JJ, Fox KA, Goldberg RJ, Budaj A, Piñero G, Avezum A, et al. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE). Heart 2003;89: 1003-8. (Pubitemid 37046830)
35. Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 2002;48: 699-707. (Pubitemid 34439101)
36. Ferraro S, Marano G, Biganzoli Elia M, Boracchi P, Bongo Angelo S. Prognostic value of cystatin C in acute coronary syndromes: enhancer of atherosclerosis and promising therapeutic target. Clin Chem Lab Med 2011;49: 1397-404.
37. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002;40: 437-45. (Pubitemid 34833157)
38. Kilic T, Oner G, Ural E, Yumuk Z, Sahin T, Bildirici U, et al. Comparison of the long-term prognostic value of Cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome. Atherosclerosis 2009;207: 552-8.
39. García Acuña JM, González-Babarro E, Grigorian Shamagian L, Peña-Gil C, Vidal Pérez R, López-Lago AM, et al. Cystatin C provides more information than other renal function parameters for stratifying risk in patients with acute coronary syndrome. Rev Esp Cardiol 2009;62: 510-9.
40. Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, et al. The transforming growth factor-βsuperfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006;98: 351-60.
41. Wollert K, Kempf T, Peter T, Olofsson S, James S, Johnston N, et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 2007;115: 962-71. (Pubitemid 46328289)
42. Eggers KM, Kempf T, Venge P, Wallentin L, Wollert KC, Lindahl B. Improving long-term risk prediction in patients with acute chest pain: the Global Registry of Acute Coronary Events (GRACE) risk score is enhanced by selected nonnecrosis biomarkers. Am Heart J 2010;160: 88-94.
43. Schaub N, Reichlin T, Twerenbold R, Reiter M, Steuer S, Bassetti S, et al. Growth differentiation factor-15 in the early diagnosis and risk stratification of patients with acute chest pain. Clin Chem 2012;58: 441-9.
44. Ishimitsu T, Ono H, Minami J, Matsuoka H. Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. Pharmacol Ther 2006;111: 909-27. (Pubitemid 44118439)
45. Adlbrecht C, Hülsmann M, Strunk G, Berger R, Mörtl D, Struck J, et al. Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients. Eur J Heart Fail 2009;11: 361-6.
46. Dhillon OS, Khan SQ, Narayan HK, Ng KH, Struck J, Quinn PA, et al. Prognostic value of mid-regional pro-adrenomedullin levels taken on admission and discharge in non-ST-elevation myocardial infarction. The LAMP (Leicester Acute Myocardial Infarction Peptide) II Study. J Am Coll Cardiol 2010;56: 125-33.
47. Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J Am Coll Cardiol 1997;29: 43-8. (Pubitemid 27028718)
48. Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet 1999;354: 1757-62.
49. Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. J Am Med Assoc 2001;286: 2405-12. (Pubitemid 33098158)
50. Hamm CW, Bassand J-P, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32: 2999-3054.
51. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. J Am Med Assoc 2001;286: 2107-13. (Pubitemid 34041595)
52. James S, Lindbäck J, Tilly J, Siegbahn A, Venge P, Armstrong P, et al. Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. J Am Coll Cardiol 2006;48: 1146-54. (Pubitemid 44345147)
53. Windhausen F, Hirsch A, Sanders GT, Cornel JP, Fischer J, van Straalen J, et al. N-terminal pro-brain natriuretic peptide for additional risk stratification in patients with non-ST-elevation acute coronary syndrome and an elevated troponin T: an Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. Am Heart J 2007;153: 485-92. (Pubitemid 46440676)
54. Van Eyk JE. Overview: the maturing of proteomics in cardiovascular research. Circ Res 2011;108: 490-8.
55. Stastna M, Van Eyk JE. Secreted proteins as a fundamental source for biomarker discovery. PROTEOMICS 2012;12: 722-35.
56. Li C, Pei F, Zhu X, Duan DD, Zeng C. Circulating microRNAs as novel and sensitive biomarkers of acute myocardial infarction. Clin Biochem 2012;45: 727-32.
57. Hoffmann U, Truong QA, Fleg JL, Goehler A, Gazelle S, Wiviott S, et al. Design of the Rule Out Myocardial Ischemia/ Infarction Using Computer Assisted Tomography: a multicenter randomized comparative effectiveness trial of cardiac computed tomography versus alternative triage strategies in patients with acute chest pain in the emergency department. Am Heart J 2012;163: 330-8.
58. Eggers KM, Lind L, Ahlström HK, Bjerner T, Ebeling Barbier C, Larsson A, et al. Prevalence and pathophysiological mechanisms of elevated cardiac troponin I levels in a population-based sample of elderly subjects. Eur Heart J 2008;29: 2252-8.
59. Eggers KM, Lagerqvist B, Venge P, Wallentin L, Lindahl B. Persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome predicts long-term mortality. Circulation 2007;11: 1907-14. (Pubitemid 350287086)